<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82834">
  <stage>Registered</stage>
  <submitdate>20/05/2008</submitdate>
  <approvaldate>28/05/2008</approvaldate>
  <actrnumber>ACTRN12608000268347</actrnumber>
  <trial_identification>
    <studytitle>The ability of a uracil breath test and a thymine loading test to correctly identify patients who have experienced severe 5-Fluorouracil (5FU) toxicity.</studytitle>
    <scientifictitle>The ability of a uracil breath test and a thymine loading test to correctly identify patients who have experienced severe 5-Fluorouracil (5FU) toxicity in patients with colorectal cancer.</scientifictitle>
    <utrn />
    <trialacronym>DPD study</trialacronym>
    <secondaryid>nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>5-Fluorouracil toxicity</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>uracil breath test (once off test), thymine assay of saliva, blood and urine, genetic analysis of blood. The testing will be completed over 2 days once informed consent is signed. These tests are not standard practice. The testing will be done on patient who exeprienced 5FU toxicity up to 1 year ago.</interventions>
    <comparator>cohort of patients without 5FU toxicity</comparator>
    <control>Active</control>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine the proportion of patients with severe 5FU toxicity have (a) abnormal Uracil breath test results and (b) abnormal thymine loading tests in saliva and urine</outcome>
      <timepoint>12 months post testing</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>to determine the proportion of patients with severe 5FU toxicity have common mutations in the gene responsible for the enzyme which breaks down 5-FU; dihydropyrimidine dehydrogenase (DPD) from a blood sample</outcome>
      <timepoint>12 month post testing</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Have recieved a solely 5FU based chemotherapy treatment in the past with severe toxicity as defined by National Cancer Institute Common Terminology Criteria for Adverse Events; grade 3-4 toxicity in 2 or more catagories with at least one hematological and one non-hematological toxicity.
No clinically significant hepatic or renal impairment.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pregnancy or breast feeding.
Any known inherited disorder of metabolism.
Any severe respiratory disorder.
Any acute or chronic gastrointestinal disorder interfering with absorption.
Inability to give written informed consent.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Case control</selection>
    <timing>Retrospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/07/2008</anticipatedstartdate>
    <actualstartdate>22/04/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate>4/11/2009</actualenddate>
    <samplesize>20</samplesize>
    <actualsamplesize>6</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Southern Health, Monash Medical Centre</primarysponsorname>
    <primarysponsoraddress>Medical Oncology
865 Centre Rd
East Beltleigh 3165</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Southern Health, Monash Medical Centre</fundingname>
      <fundingaddress>246 Clayton rd
Clayton 3168</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Southern Health, Monash Medical Centre</sponsorname>
      <sponsoraddress>Genetics Department
Familial Cancer Clinic
246 Clayton rd
Clayton 3168</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Mater Hospital</othercollaboratorname>
      <othercollaboratoraddress>biochemistry department
Brisbane
Queensland</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Trial completed with 6 subjects recruited. The breath test was not useful in predicting %FU toxicity. The Thymine test was useful in identifying soem patients with 5FU toxicity.</summary>
    <trialwebsite />
    <publication>Nil to date</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>southern health</ethicname>
      <ethicaddress>246 Clayton Rd
Clayton 3168</ethicaddress>
      <ethicapprovaldate>29/07/2008</ethicapprovaldate>
      <hrec>06060A</hrec>
      <ethicsubmitdate>22/04/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>marion harris</name>
      <address>865 centre rd
east bentleigh
3165</address>
      <phone>9928 8120</phone>
      <fax>9928 8341</fax>
      <email>marion.harris@optusnet.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>peter midolo</name>
      <address>865 centre rd
east bentleigh
3165</address>
      <phone>9928 8195</phone>
      <fax>9928 8543</fax>
      <email>peter.midolo@southernhealth.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>peter midolo</name>
      <address>865 centre rd
east bentleigh
3165</address>
      <phone>9928 8195</phone>
      <fax>9928 8543</fax>
      <email>peter.midolo@southernhealth.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Marion Harris</name>
      <address>Monash Cancer Centre
865 Centre Rd
East Bentleigh</address>
      <phone>61 3 9928 8120</phone>
      <fax>61 3 9928 8341</fax>
      <email>marion.harris@monashhealth.org</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>